CADL Stock Price, Candel Therapeutics, . Quote, Chart

Market Summary

USD11.50-1.20

Delayed

-9.45%

CADL Stock Price

View Fullscreen

CADL RSI Chart

CADL Valuation

Market Cap

342.1M

Price/Earnings (Trailing)

-9.15

Price/Sales (Trailing)

2.7K

Price/Free Cashflow

-10.63

CADL Price/Sales (Trailing)

CADL Profitability

Return on Equity

-624.94%

Return on Assets

-119.69%

Free Cashflow Yield

-9.41%

CADL Fundamentals

CADL Revenue

Revenue (TTM)

124.5K

CADL Earnings

Earnings (TTM)

-37.4M

Earnings Growth (Yr)

6.53%

Earnings Growth (Qtr)

25.9%

Breaking Down CADL Revenue

Last 7 days

23.7%

Last 30 days

112.0%

Last 90 days

570.4%

Trailing 12 Months

574.3%

How does CADL drawdown profile look like?

CADL Financial Health

Current Ratio

2

Debt/Equity

0.09

Debt/Cashflow

-56.9

CADL Investor Care

Shares Dilution (1Y)

2.85%

Diluted EPS (TTM)

-1.29

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2022	124.5K	124.5K	124.5K	124.5K
2021	124.9K	124.8K	124.6K	124.5K
2020	0	0	0	125.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Candel Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Nov 28, 2023	tyagarajan seshu	sold (taxes)	-15,595	0.9	-17,328	chief technology officer
Nov 28, 2023	barone francesca	sold (taxes)	-17,773	0.9	-19,748	chief scientific officer
Nov 28, 2023	tak paul peter	sold (taxes)	-39,098	0.9	-43,443	chief executive officer
Nov 28, 2023	nichols william garrett	sold (taxes)	-10,957	0.9	-12,175	chief medical officer
Nov 28, 2023	amello jason	sold (taxes)	-18,137	0.9	-20,153	chief financial officer
Nov 26, 2023	tyagarajan seshu	acquired	-	-	104,516	chief technology officer
Nov 26, 2023	barone francesca	acquired	-	-	112,790	chief scientific officer
Nov 26, 2023	tak paul peter	acquired	-	-	180,108	chief executive officer
Nov 26, 2023	nichols william garrett	acquired	-	-	88,822	chief medical officer
Nov 26, 2023	amello jason	acquired	-	-	125,717	chief financial officer

Which funds bought or sold CADL recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	STATE STREET CORP	unchanged	-	3,036	43,608	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	sold off	-100	-26.00	-	-%
May 15, 2024	TRAPHAGEN INVESTMENT ADVISORS LLC	new	-	27,200	27,200	-%
May 15, 2024	Northpond Ventures, LLC	unchanged	-	212,874	3,057,640	2.98%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-45.02	-4,049	5,849	-%
May 15, 2024	TWO SIGMA SECURITIES, LLC	sold off	-100	-24,270	-	-%
May 15, 2024	Mariner, LLC	new	-	52,898	52,898	-%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	new	-	21,186	21,186	-%
May 15, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	reduced	-37.71	-64,415	130,500	-%
May 15, 2024	Royal Bank of Canada	added	130	-	-	-%

Are Funds Buying or Selling CADL?

Are funds buying CADL calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CADL

No. of Funds

Unveiling Candel Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 14, 2022	northpond ventures, lp	5.9%	1,685,215	SC 13G
Feb 14, 2022	manning paul b	13.6%	4,073,316	SC 13D
Feb 09, 2022	fmr llc	-	0	SC 13G

Recent SEC filings of Candel Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
May 14, 2024	8-K	Current Report
May 14, 2024	10-Q	Quarterly Report
Apr 25, 2024	8-K	Current Report
Apr 25, 2024	10-K/A	Annual Report
Apr 11, 2024	8-K	Current Report
Apr 09, 2024	8-K	Current Report
Apr 04, 2024	8-K	Current Report
Mar 28, 2024	S-8	Employee Benefits Plan
Mar 28, 2024	8-K	Current Report
Mar 28, 2024	10-K	Annual Report

Peers (Alternatives to Candel Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Candel Therapeutics, Inc. News

Latest updates

Candel Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)											(In Thousands)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Revenue	1.6%	32.00	31.00	31.00	31.00	32.00	31.00	31.00	31.00	31.00	31.00	94.00
Operating Expenses	-8.7%	8,133	8,912	8,784	9,017	7,771	8,060	5,332	4,688	-	2,780	2,650
S&GA Expenses	-10.6%	3,161	3,536	3,762	3,600	3,910	2,795	2,040	1,935	-	967	855
R&D Expenses	-7.5%	4,972	5,376	5,022	5,417	3,861	5,265	3,292	2,753	-	1,813	1,795
Interest Expenses	45.2%	754	519	435	-175	-	-	-	-	-	-	-
Income Taxes	17.4%	27.00	23.00	48.00	85.00	1.00	7.00	15.00	6.00	-	-	-
Net Income	41.5%	-5,083	-8,688	-4,149	-874	1,596	-16,162	-17,080	-4,478	-	-2,554	-2,876
Net Income Margin	-55.1%	-150.96*	-97.31*	-157.34*	-261.20*	-290.15*	-141.87*	-141.72*	-141.58*	-	-	-
Free Cashflow	25.4%	-7,161	-9,599	-7,732	-8,224	-5,742	-7,286	-5,169	-5,856	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet													(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Assets	-24.2%	31.00	41.00	50.00	59.00	67.00	78.00	85.00	93.00	102	89.00	96.00	31.00	38.00
Current Assets	-26.3%	27.00	37.00	45.00	53.00	62.00	72.00	79.00	87.00	96.00	85.00	91.00	24.00	35.00
Cash Equivalents	-26.6%	26.00	35.00	43.00	52.00	59.00	70.00	77.00	87.00	95.00	83.00	89.00	25.00	35.00
Net PPE	-7.6%	3.00	3.00	4.00	4.00	4.00	4.00	5.00	5.00	4.00	4.00	5.00	5.00	3.00
Liabilities	-11.3%	25.00	28.00	27.00	28.00	28.00	30.00	33.00	33.00	38.00	25.00	33.00	25.00	13.00
Current Liabilities	-4.6%	14.00	14.00	10.00	8.00	5.00	6.00	6.00	6.00	5.00	5.00	4.00	4.00	5.00
Long Term Debt	-	-	-	-	-	-	-	-	-	-	1.00	1.00	1.00	0.00
LT Debt, Current	9.8%	10.00	9.00	6.00	4.00	1.00	-	-	-	-	-	-	-	-
Shareholder's Equity	-53.1%	6.00	13.00	23.00	31.00	40.00	48.00	52.00	60.00	64.00	64.00	63.00	-	-
Retained Earnings	-6.0%	-145	-137	-125	-117	-107	-99.09	-94.00	-85.30	-81.17	-80.29	-81.89	-65.73	-44.17
Additional Paid-In Capital	1.0%	151	150	149	148	148	147	146	146	145	144	145	22.00	20.00
Shares Outstanding	0.9%	29.00	29.00	29.00	29.00	29.00	29.00	29.00	29.00	29.00	29.00	23.00	12.00	-
Float	-	-	-	-	28.00	-	-	-	72.00	-	-	-	107	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Cashflow From Operations	-13.7%	-8,438	-7,422	-8,808	-7,195	-10,819	-6,885	-9,384	-7,097	-8,053	-5,238	-6,894	-4,459	-5,627	-	-	-
Share Based Compensation	11.1%	1,043	939	686	733	733	634	743	438	492	-446	1,909	1,069	431	-	-	-
Cashflow From Investing	74.1%	-7.00	-27.00	-103	-169	19.00	-276	-215	-635	-171	-504	-392	-710	-229	-	-	-
Cashflow From Financing	-Infinity%	-1,255	-	-	-	-	36.00	-	22.00	19,916	-	71,355	333	112	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

CADL Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 4,102	$ 5,469
General and administrative	3,800	4,164
Total operating expenses	7,902	9,633
Loss from operations	(7,902)	(9,633)
Other income (expense):
Grant income		12
Interest income	320	711
Interest expense	(646)	(609)
Change in fair value of warrant liability	7	724
Total other income (expense), net	(319)	838
Net loss and comprehensive loss	$ (8,221)	$ (8,795)
Net loss per share - basic	$ (0.28)	$ (0.3)
Net loss per share - diluted	$ (0.28)	$ (0.3)
Weighted-average common shares outstanding, basic	29,197,537	28,919,810
Weighted-average common shares outstanding, diluted	29,197,537	28,919,810

CADL Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 25,713	$ 35,413
Prepaid expenses and other current assets	1,423	1,384
Total current assets	27,136	36,797
Fixed assets, net	2,962	3,206
Lease right of use assets	751	816
Restricted cash	266	266
Other assets	102	116
Total assets	31,217	41,201
Current liabilities:
Accounts payable	472	422
Accrued expenses	2,772	4,356
Current portion of term loan payable to a bank	9,767	8,893
Current portion of lease liability	526	513
Total current liabilities	13,537	14,184
Term loan payable to a bank	9,174	11,632
Other long-term debt	781	751
Lease liability, net of current portion	837	973
Warrant liability	909	916
Total liabilities	25,238	28,456
Commitments and contingencies (Note 14)
Stockholders' equity
Preferred stock, $0.01 par value; 10,000,000 shares authorized at March 31, 2024 and December 31, 2023; no shares issued or outstanding at March 31, 2024 and December 31, 2023, respectively.
Common stock, $0.01 par value; 150,000,000 shares authorized at March 31, 2024 and December 31, 2023; 29,470,076 and 29,213,627 shares issued at March 31, 2024 and December 31, 2023, respectively; 29,347,468 and 29,091,019 shares outstanding at March 31, 2024 and December 31, 2023, respectively..	292	290
Treasury stock (at cost)	(448)	(448)
Additional paid-in capital	151,384	149,931
Accumulated deficit	(145,249)	(137,028)
Total stockholders' equity	5,979	12,745
Total liabilities and stockholders' equity	$ 31,217	$ 41,201

About Candel Therapeutics, Inc.

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is based in Needham, Massachusetts.

CEO	Dr. Paul-Peter Tak FMEDSCI, M.D., Ph.D.
WEBSITE	candeltx.com
INDUSTRY	Biotechnology
EMPLOYEES	76

Candel Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Candel Therapeutics, Inc.? What does CADL stand for in stocks?

CADL is the stock ticker symbol of Candel Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Candel Therapeutics, Inc. (CADL)?

As of Fri May 17 2024, market cap of Candel Therapeutics, Inc. is 342.96 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CADL stock?

You can check CADL's fair value in chart for subscribers.

What is the fair value of CADL stock?

You can check CADL's fair value in chart for subscribers. The fair value of Candel Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Candel Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CADL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Candel Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether CADL is over valued or under valued. Whether Candel Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Candel Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CADL.

What is Candel Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, CADL's PE ratio (Price to Earnings) is -9.18 and Price to Sales (PS) ratio is 2.55 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CADL PE ratio will change depending on the future growth rate expectations of investors.